Pfizer acquires 'Neksium' brand from AstraZeneca AB, Sweden

For consideration of Rs 75 crore

Pfizer has entered into an Acquisition Agreement with AstraZeneca AB, Sweden ('AstraZeneca'), pursuant to which the brand 'Neksium' is being acquired by the Company in India for a consideration of Rs. 75 crore, subject to completion of necessary conditions precedent.

Neksium (esomeprazole) complements the Company's existing product portfolio in the gastrointestinal (GI) therapeutic area.

Powered by Capital Market - Live News